Notably, in the context of human epidermal growth factor receptor 2 (HER2)–positive breast cancer patients' response to anti-HER2 therapy, Ji et al. (33) also discovered that DNAJC3 can regulate the HER2 response kinase pathway through the PI3K and MAPK signaling pathways. Here, ERBB2 is linked to breast carcinoma.